Results for tag: "Soft Tissue Sarcoma Drug"

Soft Tissue Sarcoma (STS) is a rare type of cancer that affects the connective tissues of the body, such as fat, muscle, nerves, fibrous tissues, blood vessels, and deep skin tissues. STS is typically treated with a combination of surgery, radiation, and chemotherapy. Oncology drugs are used to treat STS, including targeted therapies, immunotherapies, and hormone therapies. Targeted therapies are designed to target specific molecules or pathways in cancer cells, while immunotherapies use the body’s own immune system to fight cancer. Hormone therapies are used to block the hormones that can cause cancer cells to grow. The STS drug market is a rapidly growing segment of the oncology drug market. Companies are investing in research and development to develop new treatments for STS, as well as to improve existing treatments. Companies in the STS drug market include Pfizer, Merck, Bristol-Myers Squibb, Novartis, and AstraZeneca. Show Less Read more